- call +1-201-465-4211
- email sales@mrinsights.biz
Human Reproductive Technologies (or Assisted reproductive technology (ART)) is used to treat infertility. It includes fertility treatments that handle both a woman's egg and a man's sperm. It works by removing eggs from a woman's body. The eggs are then mixed with sperm to make embryos. The embryos are then put back in the woman's body. In vitro fertilization (IVF) is the most common and effective type of ART.
Scope of the Report:
This report studies the Human Reproductive Technologies market status and outlook of Global and major regions, from angles of players, countries, product types and end industries; this report analyzes the top players in global market, and splits the Human Reproductive Technologies market by product type and applications/end industries.
The global Human Reproductive Technologies market is valued at xx million USD in 2017 and is expected to reach xx million USD by the end of 2023, growing at a CAGR of xx% between 2017 and 2023.
The Asia-Pacific will occupy for more market share in following years, especially in China, also fast growing India and Southeast Asia regions.
North America, especially The United States, will still play an important role which cannot be ignored. Any changes from United States might affect the development trend of Human Reproductive Technologies.
Europe also play important roles in global market, with market size of xx million USD in 2017 and will be xx million USD in 2023, with a CAGR of xx%.
Market Segment by Companies, this report covers
bbott Laboratories, Inc.
Actavis, Inc.
Bayer AG
Church & Dwight, Co. Inc.
Cook Medical, Inc.
Ferring International Center S.A.
Johnson & Johnson
Merck & Co., Inc.
Merck Serono
Pfizer, Inc.
Reckitt Benckiser Group plc
Teva Pharmaceutical Industries Ltd.
Warner Chilcott plc.
Market Segment by Regions, regional analysis covers
North America (United States, Canada and Mexico)
Europe (Germany, France, UK, Russia and Italy)
Asia-Pacific (China, Japan, Korea, India and Southeast Asia)
South America (Brazil, Argentina, Colombia)
Middle East and Africa (Saudi Arabia, UAE, Egypt, Nigeria and South Africa)
Market Segment by Type, covers
In Vitro Fertilization (IVF)
Intracytoplasmic Sperm Injection (ICSI)
Zygote Intrafallopian Transfer (ZIFT)
Gamete Intrafallopian Transfer (GIFT)
Intrauterine Insemination (IUI)
Contraceptive Technology
Market Segment by Applications, can be divided into
Hospitals
Fertility Clinics
The base year for the study has been considered 2019, historic year 2014 and 2018, the forecast period considered is from 2020 to 2027. The regions analyzed for the market include North America, Europe, South America, Asia Pacific, and Middle East and Africa. These regions are further analyzed at the country-level. The study also includes attractiveness analysis of type, application and regions which are benchmarked based on their market size, growth rate and attractiveness in terms of present and future opportunity for understanding the future growth of the market.
Market is segmented on the basis:
The report offers in-depth analysis of driving factors, opportunities, restraints, and challenges for gaining the key insight of the market. The report emphasizes on all the key trends that play a vital role in the enlargement of the market from 2019 to 2026.
The report provides company profile of the key players operating in the market and a comparative analysis based on their business overviews industry offering, segment market share, regional presence, business strategies, innovations, mergers & acquisitions, recent developments, joint venture, collaborations, partnerships, SWOT analysis, and key financial information.
Table of Contents
1 Human Reproductive Technologies Market Overview
1.1 Product Overview and Scope of Human Reproductive Technologies
1.2 Classification of Human Reproductive Technologies by Types
1.2.1 Global Human Reproductive Technologies Revenue Comparison by Types (2017-2023)
1.2.2 Global Human Reproductive Technologies Revenue Market Share by Types in 2017
1.2.3 In Vitro Fertilization (IVF)
1.2.4 Intracytoplasmic Sperm Injection (ICSI)
1.2.5 Zygote Intrafallopian Transfer (ZIFT)
1.2.6 Gamete Intrafallopian Transfer (GIFT)
1.2.7 Intrauterine Insemination (IUI)
1.2.8 Contraceptive Technology
1.3 Global Human Reproductive Technologies Market by Application
1.3.1 Global Human Reproductive Technologies Market Size and Market Share Comparison by Applications (2013-2023)
1.3.2 Hospitals
1.3.3 Fertility Clinics
1.4 Global Human Reproductive Technologies Market by Regions
1.4.1 Global Human Reproductive Technologies Market Size (Million USD) Comparison by Regions (2013-2023)
1.4.1 North America (USA, Canada and Mexico) Human Reproductive Technologies Status and Prospect (2013-2023)
1.4.2 Europe (Germany, France, UK, Russia and Italy) Human Reproductive Technologies Status and Prospect (2013-2023)
1.4.3 Asia-Pacific (China, Japan, Korea, India and Southeast Asia) Human Reproductive Technologies Status and Prospect (2013-2023)
1.4.4 South America (Brazil, Argentina, Colombia) Human Reproductive Technologies Status and Prospect (2013-2023)
1.4.5 Middle East and Africa (Saudi Arabia, UAE, Egypt, Nigeria and South Africa) Human Reproductive Technologies Status and Prospect (2013-2023)
1.5 Global Market Size of Human Reproductive Technologies (2013-2023)
2 Manufacturers Profiles
2.1 bbott Laboratories, Inc.
2.1.1 Business Overview
2.1.2 Human Reproductive Technologies Type and Applications
2.1.2.1 Product A
2.1.2.2 Product B
2.1.3 bbott Laboratories, Inc. Human Reproductive Technologies Revenue, Gross Margin and Market Share (2016-2017)
2.2 Actavis, Inc.
2.2.1 Business Overview
2.2.2 Human Reproductive Technologies Type and Applications
2.2.2.1 Product A
2.2.2.2 Product B
2.2.3 Actavis, Inc. Human Reproductive Technologies Revenue, Gross Margin and Market Share (2016-2017)
2.3 Bayer AG
2.3.1 Business Overview
2.3.2 Human Reproductive Technologies Type and Applications
2.3.2.1 Product A
2.3.2.2 Product B
2.3.3 Bayer AG Human Reproductive Technologies Revenue, Gross Margin and Market Share (2016-2017)
2.4 Church & Dwight, Co. Inc.
2.4.1 Business Overview
2.4.2 Human Reproductive Technologies Type and Applications
2.4.2.1 Product A
2.4.2.2 Product B
2.4.3 Church & Dwight, Co. Inc. Human Reproductive Technologies Revenue, Gross Margin and Market Share (2016-2017)
2.5 Cook Medical, Inc.
2.5.1 Business Overview
2.5.2 Human Reproductive Technologies Type and Applications
2.5.2.1 Product A
2.5.2.2 Product B
2.5.3 Cook Medical, Inc. Human Reproductive Technologies Revenue, Gross Margin and Market Share (2016-2017)
2.6 Ferring International Center S.A.
2.6.1 Business Overview
2.6.2 Human Reproductive Technologies Type and Applications
2.6.2.1 Product A
2.6.2.2 Product B
2.6.3 Ferring International Center S.A. Human Reproductive Technologies Revenue, Gross Margin and Market Share (2016-2017)
2.7 Johnson & Johnson
2.7.1 Business Overview
2.7.2 Human Reproductive Technologies Type and Applications
2.7.2.1 Product A
2.7.2.2 Product B
2.7.3 Johnson & Johnson Human Reproductive Technologies Revenue, Gross Margin and Market Share (2016-2017)
2.8 Merck & Co., Inc.
2.8.1 Business Overview
2.8.2 Human Reproductive Technologies Type and Applications
2.8.2.1 Product A
2.8.2.2 Product B
2.8.3 Merck & Co., Inc. Human Reproductive Technologies Revenue, Gross Margin and Market Share (2016-2017)
2.9 Merck Serono
2.9.1 Business Overview
2.9.2 Human Reproductive Technologies Type and Applications
2.9.2.1 Product A
2.9.2.2 Product B
2.9.3 Merck Serono Human Reproductive Technologies Revenue, Gross Margin and Market Share (2016-2017)
2.10 Pfizer, Inc.
2.10.1 Business Overview
2.10.2 Human Reproductive Technologies Type and Applications
2.10.2.1 Product A
2.10.2.2 Product B
2.10.3 Pfizer, Inc. Human Reproductive Technologies Revenue, Gross Margin and Market Share (2016-2017)
2.11 Reckitt Benckiser Group plc
2.11.1 Business Overview
2.11.2 Human Reproductive Technologies Type and Applications
2.11.2.1 Product A
2.11.2.2 Product B
2.11.3 Reckitt Benckiser Group plc Human Reproductive Technologies Revenue, Gross Margin and Market Share (2016-2017)
2.12 Teva Pharmaceutical Industries Ltd.
2.12.1 Business Overview
2.12.2 Human Reproductive Technologies Type and Applications
2.12.2.1 Product A
2.12.2.2 Product B
2.12.3 Teva Pharmaceutical Industries Ltd. Human Reproductive Technologies Revenue, Gross Margin and Market Share (2016-2017)
2.13 Warner Chilcott plc.
2.13.1 Business Overview
2.13.2 Human Reproductive Technologies Type and Applications
2.13.2.1 Product A
2.13.2.2 Product B
2.13.3 Warner Chilcott plc. Human Reproductive Technologies Revenue, Gross Margin and Market Share (2016-2017)
3 Global Human Reproductive Technologies Market Competition, by Players
3.1 Global Human Reproductive Technologies Revenue and Share by Players (2013-2018)
3.2 Market Concentration Rate
3.2.1 Top 5 Human Reproductive Technologies Players Market Share
3.2.2 Top 10 Human Reproductive Technologies Players Market Share
3.3 Market Competition Trend
4 Global Human Reproductive Technologies Market Size by Regions
4.1 Global Human Reproductive Technologies Revenue and Market Share by Regions
4.2 North America Human Reproductive Technologies Revenue and Growth Rate (2013-2018)
4.3 Europe Human Reproductive Technologies Revenue and Growth Rate (2013-2018)
4.4 Asia-Pacific Human Reproductive Technologies Revenue and Growth Rate (2013-2018)
4.5 South America Human Reproductive Technologies Revenue and Growth Rate (2013-2018)
4.6 Middle East and Africa Human Reproductive Technologies Revenue and Growth Rate (2013-2018)
5 North America Human Reproductive Technologies Revenue by Countries
5.1 North America Human Reproductive Technologies Revenue by Countries (2013-2018)
5.2 USA Human Reproductive Technologies Revenue and Growth Rate (2013-2018)
5.3 Canada Human Reproductive Technologies Revenue and Growth Rate (2013-2018)
5.4 Mexico Human Reproductive Technologies Revenue and Growth Rate (2013-2018)
6 Europe Human Reproductive Technologies Revenue by Countries
6.1 Europe Human Reproductive Technologies Revenue by Countries (2013-2018)
6.2 Germany Human Reproductive Technologies Revenue and Growth Rate (2013-2018)
6.3 UK Human Reproductive Technologies Revenue and Growth Rate (2013-2018)
6.4 France Human Reproductive Technologies Revenue and Growth Rate (2013-2018)
6.5 Russia Human Reproductive Technologies Revenue and Growth Rate (2013-2018)
6.6 Italy Human Reproductive Technologies Revenue and Growth Rate (2013-2018)
7 Asia-Pacific Human Reproductive Technologies Revenue by Countries
7.1 Asia-Pacific Human Reproductive Technologies Revenue by Countries (2013-2018)
7.2 China Human Reproductive Technologies Revenue and Growth Rate (2013-2018)
7.3 Japan Human Reproductive Technologies Revenue and Growth Rate (2013-2018)
7.4 Korea Human Reproductive Technologies Revenue and Growth Rate (2013-2018)
7.5 India Human Reproductive Technologies Revenue and Growth Rate (2013-2018)
7.6 Southeast Asia Human Reproductive Technologies Revenue and Growth Rate (2013-2018)
8 South America Human Reproductive Technologies Revenue by Countries
8.1 South America Human Reproductive Technologies Revenue by Countries (2013-2018)
8.2 Brazil Human Reproductive Technologies Revenue and Growth Rate (2013-2018)
8.3 Argentina Human Reproductive Technologies Revenue and Growth Rate (2013-2018)
8.4 Colombia Human Reproductive Technologies Revenue and Growth Rate (2013-2018)
9 Middle East and Africa Revenue Human Reproductive Technologies by Countries
9.1 Middle East and Africa Human Reproductive Technologies Revenue by Countries (2013-2018)
9.2 Saudi Arabia Human Reproductive Technologies Revenue and Growth Rate (2013-2018)
9.3 UAE Human Reproductive Technologies Revenue and Growth Rate (2013-2018)
9.4 Egypt Human Reproductive Technologies Revenue and Growth Rate (2013-2018)
9.5 Nigeria Human Reproductive Technologies Revenue and Growth Rate (2013-2018)
9.6 South Africa Human Reproductive Technologies Revenue and Growth Rate (2013-2018)
10 Global Human Reproductive Technologies Market Segment by Type
10.1 Global Human Reproductive Technologies Revenue and Market Share by Type (2013-2018)
10.2 Global Human Reproductive Technologies Market Forecast by Type (2018-2023)
10.3 In Vitro Fertilization (IVF) Revenue Growth Rate (2013-2023)
10.4 Intracytoplasmic Sperm Injection (ICSI) Revenue Growth Rate (2013-2023)
10.5 Zygote Intrafallopian Transfer (ZIFT) Revenue Growth Rate (2013-2023)
10.6 Gamete Intrafallopian Transfer (GIFT) Revenue Growth Rate (2013-2023)
10.7 Intrauterine Insemination (IUI) Revenue Growth Rate (2013-2023)
10.8 Contraceptive Technology Revenue Growth Rate (2013-2023)
11 Global Human Reproductive Technologies Market Segment by Application
11.1 Global Human Reproductive Technologies Revenue Market Share by Application (2013-2018)
11.2 Human Reproductive Technologies Market Forecast by Application (2018-2023)
11.3 Hospitals Revenue Growth (2013-2018)
11.4 Fertility Clinics Revenue Growth (2013-2018)
12 Global Human Reproductive Technologies Market Size Forecast (2018-2023)
12.1 Global Human Reproductive Technologies Market Size Forecast (2018-2023)
12.2 Global Human Reproductive Technologies Market Forecast by Regions (2018-2023)
12.3 North America Human Reproductive Technologies Revenue Market Forecast (2018-2023)
12.4 Europe Human Reproductive Technologies Revenue Market Forecast (2018-2023)
12.5 Asia-Pacific Human Reproductive Technologies Revenue Market Forecast (2018-2023)
12.6 South America Human Reproductive Technologies Revenue Market Forecast (2018-2023)
12.7 Middle East and Africa Human Reproductive Technologies Revenue Market Forecast (2018-2023)
13 Research Findings and Conclusion
14 Appendix
14.1 Methodology
14.2 Data Source
List of Tables and Figures
Figure Human Reproductive Technologies Picture
Table Product Specifications of Human Reproductive Technologies
Table Global Human Reproductive Technologies and Revenue (Mil
ProactiveWe manage our resources 24/7 to identify issues and address them before they become problems
Quality & ReliabilityWe are committed to providing reliable and highly accurate data with an excellent quality control system
Global Outreach6 Major regions and 40+ countries level analysis accomplished
Competitive PricingOur pricing strategy is highly competitive in the market, without compensating on the quality and the timeline of project delivery
